Cannabinoid 2 receptor- and beta Arrestin 2-dependent upregulation of serotonin 2A receptors

European Neuropsychopharmacology

Volumn 23, Issue 7, 2013, Pages 760-767

  Franklin, J M ^a   Vasiljevik, T ^a   Prisinzano, T E ^a   Carrasco, G A ^a  

^a UNIVERSITY OF KANSAS   (United States)

Author keywords

Arrestins; 5 HT2A receptor; Cannabinoids; CB2 receptors; Marijuana; Receptor internalization; Serotonin

Indexed keywords

1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; BETA ARRESTIN; BETA ARRESTIN 2; CANNABINOID 2 RECEPTOR; CLATHRIN; SEROTONIN 2A RECEPTOR;

ANIMAL CELL; ANXIETY; ARTICLE; COGNITIVE DEFECT; DEPRESSION; ENDOCYTOSIS; LENTIVIRINAE; MOOD DISORDER; NERVE CELL CULTURE; NONHUMAN; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; STRESS; UPREGULATION; VIRUS PARTICLE;

ANIMALS; ARRESTINS; CANNABINOID RECEPTOR AGONISTS; CANNABINOIDS; CELLS, CULTURED; CLATHRIN; CYCLOHEXANOLS; ENDOCYTOSIS; INDENES; PYRAZOLES; RATS; RECEPTOR, CANNABINOID, CB2; RECEPTOR, SEROTONIN, 5-HT2A; RNA, SMALL INTERFERING; UP-REGULATION;

EID: 84878821415     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2012.06.012     Document Type: Article

References (38)

1. Atwood B.K., Mackie K. CB2: a cannabinoid receptor with an identity crisis. Br. J. Pharmacol. 2010, 160:467-479.
2. Atwood B.K., Wager-Miller J., Haskins C., Straiker A., Mackie K. Functional selectivity in CB(2) cannabinoid receptor signaling and regulation: implications for the therapeutic potential of CB(2) ligands. Mol. Pharmacol. 2012, 81:250-263.
3. Aung M.M., Griffin G., Huffman J.W., Wu M., Keel C., Yang B., Showalter V.M., Abood M.E., Martin B.R. Influence of the N-1 alkyl chain length of cannabimimetic indoles upon CB(1) and CB(2) receptor binding. Drug Alcohol Depend. 2000, 60:133-140.
4. Bouaboula M., Poinot-Chazel C., Marchand J., Canat X., Bourrie B., Rinaldi-Carmona M., Calandra B., Le F.G., Casellas P. Signaling pathway associated with stimulation of CB2 peripheral cannabinoid receptor. Involvement of both mitogen-activated protein kinase and induction of Krox-24 expression. Eur. J. Biochem. 1996, 237:704-711.
5. Brusco A., Tagliaferro P.A., Saez T., Onaivi E.S. Ultrastructural localization of neuronal brain CB2 cannabinoid receptors. Ann. N. Y. Acad. Sci. 2008, 1139:450-457.
6. Bubar M.J., Cunningham K.A. Serotonin 5-HT2A and 5-HT2C receptors as potential targets for modulation of psychostimulant use and dependence. Curr. Top. Med. Chem. 2006, 6:1971-1985.
7. Carrasco G.A., Van de Kar L.D. Neuroendocrine pharmacology of stress. Eur. J. Pharmacol. 2003, 463:235-272.
8. Carrasco G.A., Van de Kar L.D., Sullivan N.R., Landry M., Garcia F., Muma N.A., Battaglia G. Cocaine-mediated supersensitivity of 5-HT2A receptors in hypothalamic paraventricular nucleus is a withdrawal-induced phenomenon. Neuroscience 2006, 143:7-13.
9. Cesar Fax, 2012. 21 ed., pp. 1-2.
10. Chang F., Steelman L.S., Lee J.T., Shelton J.G., Navolanic P.M., Blalock W.L., Franklin R.A., McCubrey J.A. Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. Leukemia 2003, 17:1263-1293.
11. Darmani N.A. Cannabinoids of diverse structure inhibit two DOI-induced 5-HT(2A) receptor-mediated behaviors in mice. Pharmacol. Biochem. Behav. 2001, 68:311-317.
12. den Boon F.S., Chameau P., Schaafsma-Zhao Q., van A.W., Bari M., Oddi S., Kruse C.G., Maccarrone M., Wadman W.J., Werkman T.R. Excitability of prefrontal cortical pyramidal neurons is modulated by activation of intracellular type-2 cannabinoid receptors. Proc. Natl. Acad. Sci. U. S. A 2012, 109:3534-3539.
13. Felder C.C., ckason-Chesterfield A.K., Moore S.A. Cannabinoids biology: the search for new therapeutic targets. Mol. Interv. 2006, 6:149-161.
14. Garcia-Gutierrez M.S., Perez-Ortiz J.M., Gutierrez-Adan A., Manzanares J. Depression-resistant endophenotype in mice overexpressing cannabinoid CB(2) receptors. Br. J. Pharmacol. 2010, 160:1773-1784.
15. Gong J.P., Onaivi E.S., Ishiguro H., Liu Q.R., Tagliaferro P.A., Brusco A., Uhl G.R. Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res. 2006, 1071:10-23.
16. Gorantla S., Makarov E., Roy D., Finke-Dwyer J., Murrin L.C., Gendelman H.E., Poluektova L. Immunoregulation of a CB2 receptor agonist in a murine model of neuroAIDS. J. Neuroimmune Pharmacol. 2010, 5:456-468.
17. Griffin G., Fernando S.R., Ross R.A., McKay N.G., Ashford M.L., Shire D., Huffman J.W., Yu S., Lainton J.A., Pertwee R.G. Evidence for the presence of CB2-like cannabinoid receptors on peripheral nerve terminals. Eur. J. Pharmacol. 1997, 339:53-61.
18. Hill M.N., Sun J.C., Tse M.T., Gorzalka B.B. Altered responsiveness of serotonin receptor subtypes following long-term cannabinoid treatment. Int. J. Neuropsychopharmacol. 2006, 9:277-286.
19. Hillard C.J., Manna S., Greenberg M.J., DiCamelli R., Ross R.A., Stevenson L.A., Murphy V., Pertwee R.G., Campbell W.B. Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1). J. Pharmacol. Exp. Ther. 1999, 289:1427-1433.
20. Huffman J.W., Liddle J., Yu S., Aung M.M., Abood M.E., Wiley J.L., Martin B.R. 3-(1',1'-Dimethylbutyl)-1-deoxy-delta8-THC and related compounds: synthesis of selective ligands for the CB2 receptor. Bioorg. Med. Chem. 1999, 7:2905-2914.
21. Huffman J.W., Zengin G., Wu M.J., Lu J., Hynd G., Bushell K., Thompson A.L., Bushell S., Tartal C., Hurst D.P., Reggio P.H., Selley D.E., Cassidy M.P., Wiley J.L., Martin B.R. Structure-activity relationships for 1-alkyl-3-(1-naphthoyl)indoles at the cannabinoid CB(1) and CB(2) receptors: steric and electronic effects of naphthoyl substituents. New highly selective CB(2) receptor agonists. Bioorg. Med. Chem. 2005, 13:89-112.
22. Kawamura Y., Fukaya M., Maejima T., Yoshida T., Miura E., Watanabe M., Ohno-Shosaku T., Kano M. The CB1 cannabinoid receptor is the major cannabinoid receptor at excitatory presynaptic sites in the hippocampus and cerebellum. J. Neurosci. 2006, 26:2991-3001.
23. Large M., Sharma S., Compton M.T., Slade T., Nielssen O. Cannabis use and earlier onset of psychosis: a systematic meta-analysis. Arch. Gen. Psychiatry 2011, 68:561-565.
24. Lefkowitz R.J., Shenoy S.K. Transduction of receptor signals by beta-arrestins. Science 2005, 308:512-517.
25. Macey T.A., Ingram S.L., Bobeck E.N., Hegarty D.M., Aicher S.A., Arttamangkul S., Morgan M.M. Opioid receptor internalization contributes to dermorphin-mediated antinociception. Neuroscience 2010, 168:543-550.
26. Mato S., Alberdi E., Ledent C., Watanabe M., Matute C. CB1 cannabinoid receptor-dependent and -independent inhibition of depolarization-induced calcium influx in oligodendrocytes. Glia 2009, 57:295-306.
27. McGuinness D., Malikzay A., Visconti R., Lin K., Bayne M., Monsma F., Lunn C.A. Characterizing cannabinoid CB2 receptor ligands using DiscoveRx PathHunter beta-arrestin assay. J. Biomol. Screen. 2009, 14:49-58.
28. National Institute on Drug Abuse (NIDA), 2009. InfoFacts: Marijuana Abuse, pp. 1-5.
29. Onaivi E.S., Ishiguro H., Gong J.P., Patel S., Meozzi P.A., Myers L., Perchuk A., Mora Z., Tagliaferro P.A., Gardner E., Brusco A., Akinshola B.E., Hope B., Lujilde J., Inada T., Iwasaki S., Macharia D., Teasenfitz L., Arinami T., Uhl G.R. Brain neuronal CB2 cannabinoid receptors in drug abuse and depression: from mice to human subjects. PLoS One 2008, 3:e1640.
30. Onaivi E.S., Ishiguro H., Gong J.P., Patel S., Perchuk A., Meozzi P.A., Myers L., Mora Z., Tagliaferro P., Gardner E., Brusco A., Akinshola B.E., Liu Q.R., Hope B., Iwasaki S., Arinami T., Teasenfitz L., Uhl G.R. Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain. Ann. N. Y. Acad. Sci. 2006, 1074:514-536.
31. Roth B.L. Irving Page Lecture: 5-HT(2A) serotonin receptor biology: interacting proteins, kinases and paradoxical regulation. Neuropharmacology 2011, 61:348-354.
32. Rutkowska M., Jachimczuk O. Antidepressant-like properties of ACEA (arachidonyl-2-chloroethylamide), the selective agonist of CB1 receptors. Acta Pol. Pharm. 2004, 61:165-167.
33. Shoemaker J.L., Ruckle M.B., Mayeux P.R., Prather P.L. Agonist-directed trafficking of response by endocannabinoids acting at CB2 receptors. J. Pharmacol. Exp. Ther. 2005, 315:828-838.
34. Showalter V.M., Compton D.R., Martin B.R., Abood M.E. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J. Pharmacol. Exp. Ther. 1996, 278:989-999.
35. Singh R.K., Jia C., Garcia F., Carrasco G.A., Battaglia G., Muma N.A. Activation of the JAK-STAT pathway by olanzapine is necessary for desensitization of serotonin2A receptor-stimulated phospholipase C signaling in rat frontal cortex but not serotonin2A receptor-stimulated hormone release. J. Psychopharmacol. 2010, 24:1079-1088.
36. Singh R.K., Shi J., Zemaitaitis B.W., Muma N.A. Olanzapine increases RGS7 protein expression via stimulation of the Janus tyrosine kinase-signal transducer and activator of transcription signaling cascade. J. Pharmacol. Exp. Ther. 2007, 322:133-140.
37. Trincavelli M.L., Tuscano D., Cecchetti P., Falleni A., Benzi L., Klotz K.N., Gremigni V., Cattabeni F., Lucacchini A., Martini C. Agonist-induced internalization and recycling of the human A(3) adenosine receptors: role in receptor desensitization and resensitization. J. Neurochem. 2000, 75:1493-1501.
38. Yang C.H., Huang H.W., Chen K.H., Chen Y.S., Sheen-Chen S.M., Lin C.R. Antinociceptive potentiation and attenuation of tolerance by intrathecal beta-arrestin 2 small interfering RNA in rats. Br. J. Anaesth. 2011, 107:774-781.